Literature DB >> 34699177

Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells.

Feyisola P Olatunji1, Emily A Savoy1, Mylan Panteah2, Nooshin Mesbahi1, Armina Abbasi1, Cresencia M Talley1, Christine L Lovingier1, Leslie A Caromile2, Clifford E Berkman1.   

Abstract

The tunable nature of phosphoramidate linkers enables broad applicability as pH-triggered controlled-release platforms, particularly in the context of antibody- and small-molecule-drug conjugates (ADCs and SMDCs), where there remains a need for new linker technology. Herein, we explored in-depth the release of turn-on fluorogenic payloads from a homoserinyl-based phosphoramidate acid-cleavable linker. Kinetics of payload release from the scaffold was observed in buffers representing the pH conditions of systemic circulation, early and late endosomes, and lysosomes. It was found that payload release takes place in two key consecutive steps: (1) P-N bond hydrolysis and (2) spacer immolation. These two steps were found to follow pseudo-first-order kinetics and had opposite dependencies on pH. P-N bond hydrolysis increased with decreasing pH, while spacer immolation was most rapid at physiological pH. Despite the contrasting release kinetics of these two steps, maximal payload release was observed at the mildly acidic pH (5.0-5.5), while minimal payload release occurred at physiological pH. We integrated this phosphoramidate-payload linker system into a PSMA-targeted fluorescent turn-on probe to study the intracellular trafficking and release of a fluorescent payload in PSMA-expressing prostate cancer cells. Results showed excellent turn-on and accumulation of the coumarin payload in the late endosomal and lysosomal compartments of these cells. The release properties of this linker mark it as an attractive alternative in the modular design of ADCs and SMDCs, which demand selective intracellular payload release triggered by the pH changes that accompany intracellular trafficking.

Entities:  

Mesh:

Year:  2021        PMID: 34699177      PMCID: PMC8729914          DOI: 10.1021/acs.bioconjchem.1c00435

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  59 in total

Review 1.  A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?

Authors:  J Tasch; M Gong; M Sadelain; W D Heston
Journal:  Crit Rev Immunol       Date:  2001       Impact factor: 2.214

2.  Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography.

Authors:  Tomás R Guilarte; Jennifer L McGlothan; Catherine A Foss; Jia Zhou; Warren D Heston; Alan P Kozikowski; Martin G Pomper
Journal:  Neurosci Lett       Date:  2005-10-28       Impact factor: 3.046

3.  Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.

Authors:  Xiaoxi Ling; Joseph D Latoche; Cindy J Choy; Brenda F Kurland; Charles M Laymon; Yijen Wu; Nathan Salamacha; Ding Shen; Jonathan J Geruntho; Lora H Rigatti; Hillarie P Windish; Beatrice Langton-Webster; Clifford E Berkman; Carolyn J Anderson
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

Review 4.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

5.  Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

Authors:  Matthew I Milowsky; David M Nanus; Lale Kostakoglu; Christine E Sheehan; Shankar Vallabhajosula; Stanley J Goldsmith; Jeffrey S Ross; Neil H Bander
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

6.  Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen.

Authors:  Corinne R Ley; Nathan R Beattie; Shorouk Dannoon; Melanie Regan; Henry VanBrocklin; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2015-04-29       Impact factor: 2.823

7.  Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates.

Authors:  Ted C Chu; Felice Shieh; Laura A Lavery; Matthew Levy; Rebecca Richards-Kortum; Brian A Korgel; Andrew D Ellington
Journal:  Biosens Bioelectron       Date:  2006-02-21       Impact factor: 10.618

8.  Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.

Authors:  R S Israeli; C T Powell; W R Fair; W D Heston
Journal:  Cancer Res       Date:  1993-01-15       Impact factor: 12.701

9.  Tunable pH-Sensitive 2-Carboxybenzyl Phosphoramidate Cleavable Linkers.

Authors:  Brian S Backer; Cindy J Choy; Austen L Davis; Zachery S Browne; Clifford E Berkman
Journal:  Tetrahedron Lett       Date:  2020-01-25       Impact factor: 2.415

Review 10.  Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?

Authors:  Mahendra P Deonarain; Gokhan Yahioglu; Ioanna Stamati; Anja Pomowski; James Clarke; Bryan M Edwards; Soraya Diez-Posada; Ashleigh C Stewart
Journal:  Antibodies (Basel)       Date:  2018-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.